A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial

被引：0
|
作者：
Jian Hou
Xin Du
Jie Jin
Zhen Cai
Fangping Chen
Dao-bin Zhou
Li Yu
Xiaoyan Ke
Xiao Li
Depei Wu
Fanyi Meng
Huisheng Ai
Jingshan Zhang
Honeylet Wortman-Vayn
Nianhang Chen
Jay Mei
Jianmin Wang
机构：
[1] Shanghai Changzheng Hospital,Department of Hematology
[2] Guangdong General Hospital,The 1st Hospital
[3] Zhejiang University,undefined
[4] Xiangya Hospital of Central South University,undefined
[5] Peking Union Medical College Hospital,undefined
[6] The 301 Hospital-Chinese PLA General Hospital,undefined
[7] Peking University Third Hospital,undefined
[8] Shanghai 6th Hospital,undefined
[9] The 1st Affiliated Hospital of Soochow University,undefined
[10] Nanfang Hospital of Southern Medicine University in Guangzhou,undefined
[11] The 307 PLA Hospital,undefined
[12] Celgene Corporation,undefined
[13] Changhai Hospital,undefined
来源：
Journal of Hematology & Oncology | / 6卷
关键词：
Relapsed/Refractory Multiple Myeloma; Chinese Patients; Lenalidomide; Low-dose Dexamethasone;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial
    Hou, Jian
    Du, Xin
    Jin, Jie
    Cai, Zhen
    Chen, Fangping
    Zhou, Dao-bin
    Yu, Li
    Ke, Xiaoyan
    Li, Xiao
    Wu, Depei
    Meng, Fanyi
    Ai, Huisheng
    Zhang, Jingshan
    Wortman-Vayn, Honeylet
    Chen, Nianhang
    Mei, Jay
    Wang, Jianmin
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6
  • [2] Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment
    Dao-bin Zhou
    Li Yu
    Xin Du
    Jie Jin
    Zhen Cai
    Fangping Chen
    Xiaoyan Ke
    Xiao Li
    Depei Wu
    Fanyi Meng
    Huisheng Ai
    Jingshan Zhang
    Dena DeMarco
    Nianhang Chen
    Jay Mei
    Jianmin Wang
    Jian Hou
    International Journal of Hematology, 2015, 101 : 569 - 577
  • [3] Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment
    Zhou, Dao-bin
    Yu, Li
    Du, Xin
    Jin, Jie
    Cai, Zhen
    Chen, Fangping
    Ke, Xiaoyan
    Li, Xiao
    Wu, Depei
    Meng, Fanyi
    Ai, Huisheng
    Zhang, Jingshan
    DeMarco, Dena
    Chen, Nianhang
    Mei, Jay
    Wang, Jianmin
    Hou, Jian
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 101 (06) : 569 - 577
  • [4] Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
    San Miguel, Jesus
    Weisel, Katja
    Moreau, Philippe
    Lacy, Martha
    Song, Kevin
    Delforge, Michel
    Karlin, Lionel
    Goldschmidt, Hartmut
    Banos, Anne
    Oriol, Albert
    Alegre, Adrian
    Chen, Christine
    Cavo, Michele
    Garderet, Laurent
    Ivanova, Valentina
    Martinez-Lopez, Joaquin
    Belch, Andrew
    Palumbo, Antonio
    Schey, Stephen
    Sonneveld, Pieter
    Yu, Xin
    Sternas, Lars
    Jacques, Christian
    Zaki, Mohamed
    Dimopoulos, Meletios
    LANCET ONCOLOGY, 2013, 14 (11): : 1055 - 1066
  • [5] Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program
    Du, Xin
    Jin, Jie
    Cai, Zhen
    Chen, Fangping
    Zhou, Dao-bin
    Yu, Li
    Ke, Xiaoyan
    Li, Xiao
    Wu, Depei
    Meng, Fanyi
    DeMarco, Dena
    Zhang, Jingshan
    Mei, Jay
    Hou, Jian
    BMC CANCER, 2016, 16
  • [6] Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program
    Xin Du
    Jie Jin
    Zhen Cai
    Fangping Chen
    Dao-bin Zhou
    Li Yu
    Xiaoyan Ke
    Xiao Li
    Depei Wu
    Fanyi Meng
    Dena DeMarco
    Jingshan Zhang
    Jay Mei
    Jian Hou
    BMC Cancer, 16
  • [7] Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial
    Fu, Wei-Jun
    Wang, Ya-Fei
    Zhao, Hong-Guo
    Niu, Ting
    Fang, Bai-Jun
    Liao, Ai-Jun
    Bai, Hai
    Lu, Jin
    BMC CANCER, 2022, 22 (01)
  • [8] Impact of depression on adherence to lenalidomide plus low-dose dexamethasone in patients with relapsed or refractory myeloma
    Seok Jin Kim
    Danbee Kang
    Yong Park
    Yeung-Chul Mun
    Kihyun Kim
    Jin Seok Kim
    Chang-Ki Min
    Juhee Cho
    Supportive Care in Cancer, 2021, 29 : 4969 - 4977
  • [9] Impact of depression on adherence to lenalidomide plus low-dose dexamethasone in patients with relapsed or refractory myeloma
    Kim, Seok Jin
    Kang, Danbee
    Park, Yong
    Mun, Yeung-Chul
    Kim, Kihyun
    Kim, Jin Seok
    Min, Chang-Ki
    Cho, Juhee
    SUPPORTIVE CARE IN CANCER, 2021, 29 (09) : 4969 - 4977
  • [10] Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial
    Wei-Jun Fu
    Ya-Fei Wang
    Hong-Guo Zhao
    Ting Niu
    Bai-Jun Fang
    Ai-Jun Liao
    Hai Bai
    Jin Lu
    BMC Cancer, 22
12345